Novartis Gets Approval For New Standard Formulation Of Bronchial Asthma Drug Xolair
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharmaceuticals announced Sept. 20 it received approval for a new standard formulation of the bronchial asthma drug Xolair.